Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

APOE-ε4 risk variant for Alzheimer's disease modifies the association between cognitive performance and cerebral morphology in healthy middle-aged individuals.

Cacciaglia R, Molinuevo JL, Falcón C, Sánchez-Benavides G, Gramunt N, Brugulat-Serrat A, Esteller M, Morán S, Fauria K, Gispert JD; ALFA study.

Neuroimage Clin. 2019 Apr 8;23:101818. doi: 10.1016/j.nicl.2019.101818. [Epub ahead of print]

2.

CSF glial biomarkers YKL40 and sTREM2 are associated with longitudinal volume and diffusivity changes in cognitively unimpaired individuals.

Falcon C, Monté-Rubio GC, Grau-Rivera O, Suárez-Calvet M, Sánchez-Valle R, Rami L, Bosch B, Haass C, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019 Apr 1;23:101801. doi: 10.1016/j.nicl.2019.101801. [Epub ahead of print]

3.

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies.

Heeman F, Yaqub M, Lopes Alves I, Heurling K, Berkhof J, Gispert JD, Bullich S, Foley C, Lammertsma AA; AMYPAD Consortium.

EJNMMI Res. 2019 Mar 27;9(1):32. doi: 10.1186/s13550-019-0499-4.

4.

Mechanisms of functional compensation, delineated by eigenvector centrality mapping, across the pathophysiological continuum of Alzheimer's disease.

Skouras S, Falcon C, Tucholka A, Rami L, Sanchez-Valle R, Lladó A, Gispert JD, Molinuevo JL.

Neuroimage Clin. 2019;22:101777. doi: 10.1016/j.nicl.2019.101777. Epub 2019 Mar 12.

5.

Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers.

Salvadó G, Molinuevo JL, Brugulat-Serrat A, Falcon C, Grau-Rivera O, Suárez-Calvet M, Pavia J, Niñerola-Baizán A, Perissinotti A, Lomeña F, Minguillon C, Fauria K, Zetterberg H, Blennow K, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study.

Alzheimers Res Ther. 2019 Mar 21;11(1):27. doi: 10.1186/s13195-019-0478-z.

6.

Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.

Salvadó G, Brugulat-Serrat A, Sudre CH, Grau-Rivera O, Suárez-Calvet M, Falcon C, Fauria K, Cardoso MJ, Barkhof F, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2019 Jan 24;11(1):12. doi: 10.1186/s13195-018-0460-1.

7.

Brain and cognitive correlates of subjective cognitive decline-plus features in a population-based cohort.

Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Minguillon C, Cacciaglia R, Gramunt N, Falcon C; ALFA Study, Gispert JD, Molinuevo JL.

Alzheimers Res Ther. 2018 Dec 20;10(1):123. doi: 10.1186/s13195-018-0449-9.

8.

Secondary prevention of Alzheimer's dementia: neuroimaging contributions.

Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F.

Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z.

9.

AMYPAD Diagnostic and Patient Management Study: Rationale and design.

Frisoni GB, Barkhof F, Altomare D, Berkhof J, Boccardi M, Canzoneri E, Collij L, Drzezga A, Farrar G, Garibotto V, Gismondi R, Gispert JD, Jessen F, Kivipelto M, Lopes Alves I, Molinuevo JL, Nordberg A, Payoux P, Ritchie C, Savicheva I, Scheltens P, Schmidt ME, Schott JM, Stephens A, van Berckel B, Vellas B, Walker Z, Raffa N.

Alzheimers Dement. 2019 Mar;15(3):388-399. doi: 10.1016/j.jalz.2018.09.003. Epub 2018 Oct 16.

10.

Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.

Falcon C, Tucholka A, Monté-Rubio GC, Cacciaglia R, Operto G, Rami L, Gispert JD, Molinuevo JL; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.

11.

Distinct Cognitive and Brain Morphological Features in Healthy Subjects Unaware of Informant-Reported Cognitive Decline.

Sánchez-Benavides G, Grau-Rivera O, Cacciaglia R, Suárez-Calvet M, Falcon C, Minguillon C, Gramunt N, Sala-Vila A, Gispert JD, Molinuevo JL.

J Alzheimers Dis. 2018;65(1):181-191. doi: 10.3233/JAD-180378.

12.

MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials.

Casamitjana A, Petrone P, Tucholka A, Falcon C, Skouras S, Molinuevo JL, Vilaplana V, Gispert JD; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(4):1099-1112. doi: 10.3233/JAD-180299.

PMID:
30010132
13.

Episodic memory and executive functions in cognitively healthy individuals display distinct neuroanatomical correlates which are differentially modulated by aging.

Cacciaglia R, Molinuevo JL, Sánchez-Benavides G, Falcón C, Gramunt N, Brugulat-Serrat A, Grau O, Gispert JD; ALFA Study.

Hum Brain Mapp. 2018 Nov;39(11):4565-4579. doi: 10.1002/hbm.24306. Epub 2018 Jul 4.

14.

White matter microstructure is altered in cognitively normal middle-aged APOE-ε4 homozygotes.

Operto G, Cacciaglia R, Grau-Rivera O, Falcon C, Brugulat-Serrat A, Ródenas P, Ramos R, Morán S, Esteller M, Bargalló N, Molinuevo JL, Gispert JD; ALFA Study.

Alzheimers Res Ther. 2018 May 24;10(1):48. doi: 10.1186/s13195-018-0375-x.

15.

Effects of APOE-ε4 allele load on brain morphology in a cohort of middle-aged healthy individuals with enriched genetic risk for Alzheimer's disease.

Cacciaglia R, Molinuevo JL, Falcón C, Brugulat-Serrat A, Sánchez-Benavides G, Gramunt N, Esteller M, Morán S, Minguillón C, Fauria K, Gispert JD; ALFA study.

Alzheimers Dement. 2018 Jul;14(7):902-912. doi: 10.1016/j.jalz.2018.01.016. Epub 2018 Mar 28.

16.

The Rationale Behind the New Alzheimer's Disease Conceptualization: Lessons Learned During the Last Decades.

Molinuevo JL, Minguillon C, Rami L, Gispert JD.

J Alzheimers Dis. 2018;62(3):1067-1077. doi: 10.3233/JAD-170698. Review.

17.

Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies.

Falcon C, Operto G, Molinuevo JL, Gispert JD.

Methods Mol Biol. 2018;1750:165-184. doi: 10.1007/978-1-4939-7704-8_11.

PMID:
29512072
18.

The Crus exhibits stronger functional connectivity with executive network nodes than with the default mode network.

Skouras S, Gispert JD, Molinuevo JL.

Brain. 2018 Apr 1;141(4):e24. doi: 10.1093/brain/awy025. No abstract available.

PMID:
29471474
19.

Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid-β and Tau.

Tucholka A, Grau-Rivera O, Falcon C, Rami L, Sánchez-Valle R, Lladó A, Gispert JD, Molinuevo JL; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;61(4):1575-1587. doi: 10.3233/JAD-170553.

20.

Learning non-linear patch embeddings with neural networks for label fusion.

Sanroma G, Benkarim OM, Piella G, Camara O, Wu G, Shen D, Gispert JD, Molinuevo JL, González Ballester MA; Alzheimer’s Disease Neuroimaging Initiative.

Med Image Anal. 2018 Feb;44:143-155. doi: 10.1016/j.media.2017.11.013. Epub 2017 Dec 2.

21.

A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease.

Demirtaş M, Falcon C, Tucholka A, Gispert JD, Molinuevo JL, Deco G.

Neuroimage Clin. 2017 Aug 8;16:343-354. doi: 10.1016/j.nicl.2017.08.006. eCollection 2017.

22.

Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-ɛ4 allele carriers aged 45-75: Results from the ALFA study.

Rojas S, Brugulat-Serrat A, Bargalló N, Minguillón C, Tucholka A, Falcon C, Carvalho A, Morán S, Esteller M, Gramunt N, Fauria K, Camí J, Molinuevo JL, Gispert JD.

J Cereb Blood Flow Metab. 2018 Feb;38(2):250-261. doi: 10.1177/0271678X17707397. Epub 2017 May 11.

23.

Changes in cerebral [18F]-FDG uptake induced by acute alcohol administration in a rat model of alcoholism.

Gispert JD, Figueiras FP, Vengeliene V, Herance JR, Rojas S, Spanagel R.

Behav Brain Res. 2017 Jun 1;327:29-33. doi: 10.1016/j.bbr.2017.03.038. Epub 2017 Mar 27.

PMID:
28347826
24.

Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with Alzheimer's disease: a cross-sectional analysis from the ALFA (Alzheimer and Families) project.

Brugulat-Serrat A, Rojas S, Bargalló N, Conesa G, Minguillón C, Fauria K, Gramunt N, Molinuevo JL, Gispert JD.

BMJ Open. 2017 Mar 24;7(3):e013215. doi: 10.1136/bmjopen-2016-013215.

25.

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2.

Gispert JD, Monté GC, Suárez-Calvet M, Falcon C, Tucholka A, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement (Amst). 2016 Dec 22;6:50-59. doi: 10.1016/j.dadm.2016.12.002. eCollection 2017.

26.

Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.

van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM.

J Alzheimers Dis. 2017;56(2):543-555. doi: 10.3233/JAD-160668.

PMID:
28059783
27.

Modeling practice effects in healthy middle-aged participants of the Alzheimer and Families parent cohort.

Sánchez-Benavides G, Gispert JD, Fauria K, Molinuevo JL, Gramunt N.

Alzheimers Dement (Amst). 2016 Aug 30;4:149-158. eCollection 2016.

28.

Characterization of the Biodistribution and Systemic Absorption of TT-173, a New Hemostatic Agent of Recombinant Human Tissue Factor, Using Radiolabeling with 18F.

Rojas S, Herance JR, Gispert JD, Arias B, Miquel I, López R, Sánchez P, Rincón E, Murat J.

Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):583-592. doi: 10.1007/s13318-016-0366-x.

PMID:
27550654
29.

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.

Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement. 2016 Dec;12(12):1259-1272. doi: 10.1016/j.jalz.2016.06.005. Epub 2016 Jul 14.

PMID:
27423963
30.

The Memory Binding Test: Development of Two Alternate Forms into Spanish and Catalan.

Gramunt N, Sánchez-Benavides G, Buschke H, Diéguez-Vide F, Peña-Casanova J, Masramon X, Fauria K, Gispert JD, Molinuevo JL.

J Alzheimers Dis. 2016 Mar 5;52(1):283-93. doi: 10.3233/JAD-151175.

PMID:
27060959
31.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123. Print 2016 May.

32.

The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease.

Molinuevo JL, Gramunt N, Gispert JD, Fauria K, Esteller M, Minguillon C, Sánchez-Benavides G, Huesa G, Morán S, Dal-Ré R, Camí J.

Alzheimers Dement (N Y). 2016 Mar 3;2(2):82-92. doi: 10.1016/j.trci.2016.02.003. eCollection 2016 Jun.

33.

Psychometric Properties of the Memory Binding Test: Test-Retest Reliability and Convergent Validity.

Gramunt N, Sánchez-Benavides G, Buschke H, Lipton RB, Masramon X, Gispert JD, Peña-Casanova J, Fauria K, Molinuevo JL.

J Alzheimers Dis. 2016;50(4):999-1010. doi: 10.3233/JAD-150776.

PMID:
26836167
34.

CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.

Gispert JD, Monté GC, Falcon C, Tucholka A, Rojas S, Sánchez-Valle R, Antonell A, Lladó A, Rami L, Molinuevo JL.

Neurobiol Aging. 2016 Feb;38:47-55. doi: 10.1016/j.neurobiolaging.2015.10.022. Epub 2015 Nov 2.

PMID:
26827642
35.

Environment and Brain Development: Challenges in the Global Context.

Júlvez J, Paus T, Bellinger D, Eskenazi B, Tiemeier H, Pearce N, Ritz B, White T, Ramchandani P, Gispert JD, Desrivières S, Brouwer R, Boucher O, Alemany S, López-Vicente M, Suades-González E, Forns J, Grandjean P, Sunyer J.

Neuroepidemiology. 2016;46(2):79-82. doi: 10.1159/000442256. Epub 2015 Dec 19. No abstract available.

36.

Reference Data of the Spanish Memory Binding Test in a Midlife Population from the ALFA STUDY (Alzheimer's and Family).

Gramunt N, Buschke H, Sánchez-Benavides G, Lipton RB, Peña-Casanova J, Diéguez-Vide F, Masramon X, Gispert JD, Fauria K, Camí J, Molinuevo JL.

J Alzheimers Dis. 2015;48(3):613-25. doi: 10.3233/JAD-150237.

PMID:
26402091
37.

Nonlinear cerebral atrophy patterns across the Alzheimer's disease continuum: impact of APOE4 genotype.

Gispert JD, Rami L, Sánchez-Benavides G, Falcon C, Tucholka A, Rojas S, Molinuevo JL.

Neurobiol Aging. 2015 Oct;36(10):2687-701. doi: 10.1016/j.neurobiolaging.2015.06.027. Epub 2015 Jul 8.

PMID:
26239178
38.

Monte Carlo simulations versus experimental measurements in a small animal PET system. A comparison in the NEMA NU 4-2008 framework.

Popota FD, Aguiar P, España S, Lois C, Udias JM, Ros D, Pavia J, Gispert JD.

Phys Med Biol. 2015 Jan 7;60(1):151-62. doi: 10.1088/0031-9155/60/1/151. Epub 2014 Dec 5.

PMID:
25479341
39.

Quantification of rat brain SPECT with (123)I-ioflupane: evaluation of different reconstruction methods and image degradation compensations using Monte Carlo simulation.

Roé-Vellvé N, Pino F, Falcon C, Cot A, Gispert JD, Marin C, Pavía J, Ros D.

Phys Med Biol. 2014 Aug 21;59(16):4567-82. doi: 10.1088/0031-9155/59/16/4567. Epub 2014 Jul 28.

PMID:
25069105
40.

Diazepam and Jacobson's progressive relaxation show similar attenuating short-term effects on stress-related brain glucose consumption.

Pifarré P, Simó M, Gispert JD, Plaza P, Fernández A, Pujol J.

Eur Psychiatry. 2015 Feb;30(2):187-92. doi: 10.1016/j.eurpsy.2014.03.002. Epub 2014 Jun 5.

PMID:
24908148
41.

Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB.

Burokas A, Martín-García E, Gutiérrez-Cuesta J, Rojas S, Herance JR, Gispert JD, Serra MÁ, Maldonado R.

J Neurochem. 2014 Jul;130(1):126-35. doi: 10.1111/jnc.12716. Epub 2014 Apr 30.

42.

A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells.

Puig I, Chicote I, Tenbaum SP, Arqués O, Herance JR, Gispert JD, Jimenez J, Landolfi S, Caci K, Allende H, Mendizabal L, Moreno D, Charco R, Espín E, Prat A, Elez ME, Argilés G, Vivancos A, Tabernero J, Rojas S, Palmer HG.

Clin Cancer Res. 2013 Dec 15;19(24):6787-801. doi: 10.1158/1078-0432.CCR-12-1740. Epub 2013 Oct 29.

43.

Assessing lung inflammation after nanoparticle inhalation using 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography imaging.

Pérez-Campaña C, Gómez-Vallejo V, Puigivila M, Martin A, Calvo-Fernández T, Moya SE, Larsen ST, Gispert JD, Llop J.

Mol Imaging Biol. 2014 Apr;16(2):264-73. doi: 10.1007/s11307-013-0682-3.

PMID:
24002615
44.

Optimization of [(11)C]raclopride positron emission tomographic rat studies: comparison of methods for image quantification.

Torrent E, Farré M, Abasolo I, Millan O, Llop J, Gispert JD, Ruiz A, Pareto D.

Mol Imaging. 2013 Jun;12(4):257-62.

PMID:
23651503
45.

Erythrocytes labeled with [(18) F]SFB as an alternative to radioactive CO for quantification of blood volume with PET.

Herance JR, Gispert JD, Abad S, Victor VM, Pareto D, Torrent È, Rojas S.

Contrast Media Mol Imaging. 2013 Jul-Aug;8(4):375-81. doi: 10.1002/cmmi.1533.

PMID:
23613441
46.

The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study.

Molinuevo JL, Gispert JD, Dubois B, Heneka MT, Lleo A, Engelborghs S, Pujol J, de Souza LC, Alcolea D, Jessen F, Sarazin M, Lamari F, Balasa M, Antonell A, Rami L.

J Alzheimers Dis. 2013;36(1):67-77. doi: 10.3233/JAD-130203.

PMID:
23524657
47.

In vivo evaluation of amyloid deposition and brain glucose metabolism of 5XFAD mice using positron emission tomography.

Rojas S, Herance JR, Gispert JD, Abad S, Torrent E, Jiménez X, Pareto D, Perpiña U, Sarroca S, Rodríguez E, Ortega-Aznar A, Sanfeliu C.

Neurobiol Aging. 2013 Jul;34(7):1790-8. doi: 10.1016/j.neurobiolaging.2012.12.027. Epub 2013 Feb 10.

PMID:
23402900
48.

In vivo biodistribution of amino-functionalized ceria nanoparticles in rats using positron emission tomography.

Rojas S, Gispert JD, Abad S, Buaki-Sogo M, Victor VM, Garcia H, Herance JR.

Mol Pharm. 2012 Dec 3;9(12):3543-50. doi: 10.1021/mp300382n. Epub 2012 Nov 20.

PMID:
23140442
49.

β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S Jr, Vivancos A, Espín E, Rojas S, Baselga J, Tabernero J, Muñoz A, Palmer HG.

Nat Med. 2012 Jun;18(6):892-901. doi: 10.1038/nm.2772.

PMID:
22610277
50.

Gaba and serotonin molecular neuroimaging in essential tremor: a clinical correlation study.

Gironell A, Figueiras FP, Pagonabarraga J, Herance JR, Pascual-Sedano B, Trampal C, Gispert JD.

Parkinsonism Relat Disord. 2012 Aug;18(7):876-80. doi: 10.1016/j.parkreldis.2012.04.024. Epub 2012 May 16.

PMID:
22595620

Supplemental Content

Loading ...
Support Center